Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
about
Development of targeted therapies in treatment of glioblastomaPreclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor modelsGlial progenitors as targets for transformation in glioma.The challenges and the promise of molecular targeted therapy in malignant gliomas.Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human gliomaNovel therapies in glioblastoma.Upregulation of SATB1 is associated with the development and progression of glioma.Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potencyPathway-based personalized analysis of cancerMolecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells.Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.PDGFRα depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signalsTargeting the VEGF and PDGF signaling pathway in glioblastoma treatment.Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies.Small molecule-mediated induction of miR-9 suppressed vascular smooth muscle cell proliferation and neointima formation after balloon injury.High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response.
P2860
Q26778787-DC29148B-8CDB-4948-AE28-2D69EA75C345Q33578960-9324E878-4AF8-48C0-84EB-087584185C72Q34735661-07DFF821-8A6D-4E31-AEAA-9C3DD2002193Q35214534-6318152D-FB58-4EE3-BD77-900C9FF9FBABQ35252433-E350BE39-348D-42A8-97CA-90602F48DB9EQ35864136-503D680A-6960-44EC-90CC-FF6B629CAE5EQ36380379-FC5DB858-5887-4C79-A477-A3E8DFB75896Q36511049-F94F7D5D-D16E-4D24-8708-806949250EF7Q36782228-EDCBD016-4C50-481D-8A9C-9A1CDA5FB7E9Q36879252-859FB973-93AB-40D8-A8FB-8E5221BF5533Q36946655-245408D3-D4A2-4330-B11C-F9A8C2A50999Q36996552-EAC0D045-E3B1-45E4-BC60-F634DA4218F6Q37619702-6DF8D6C4-5F14-4046-B4C8-B978B38CDD61Q38838030-66ACA476-F4F5-40EC-B378-A321F1F82C85Q38962315-C04A00F4-7077-47EE-BF21-ECE78CE7B1A8Q39521993-9809B423-705B-4A96-A764-963C6DF43313Q47100278-759C2F4E-3FA0-4FDF-937B-AAC75B46C2CBQ48334668-7758E74A-3682-493E-923B-31217B2357D1
P2860
Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Selective inhibition of PDGFR ...... ing in malignant glioma cells.
@en
Selective inhibition of PDGFR ...... ing in malignant glioma cells.
@nl
type
label
Selective inhibition of PDGFR ...... ing in malignant glioma cells.
@en
Selective inhibition of PDGFR ...... ing in malignant glioma cells.
@nl
prefLabel
Selective inhibition of PDGFR ...... ing in malignant glioma cells.
@en
Selective inhibition of PDGFR ...... ing in malignant glioma cells.
@nl
P2093
P356
P1476
Selective inhibition of PDGFR ...... ling in malignant glioma cells
@en
P2093
Jiankai Xu
Xiaohua Wang
Xiaoqing Tan
Yucui Dong
Zhenling Deng
P304
P356
10.3892/IJO.2010.861
P577
2010-12-06T00:00:00Z